LikeMinds, Inc.


When it comes to degenerative brain diseases like Parkinson’s, dementia and other dopamine transporter related diseases, early detection matters. These diseases can progress undetected for more than a decade before clinical symptoms appear. By then, the number of fully functional dopamine transporters in the brain may have declined significantly, leading to diseases like Parkinson’s and Lewy Body Dementia. Early, accurate detection is critical to developing and taking advantage of potential disease-modifying therapeutics.

LikeMinds’ mission is to provide a precise, early, accurate and therefore actionable diagnosis of Parkinson’s Disease, Lewy Body Dementia and other dopamine transporter related brain diseases using its dopamine transporter imaging agent, DaT2020.

Diagnostic precision in imaging aids in the differential diagnosis and subsequent treatment of people with Parkinson’s disease and Essential Tremor. Charles Adler published in Neurology in July, 2014 that without precision brain imaging, clinical diagnosis error rates range from 50% – 74%, preventing physicians and scientists from having access to the early stage patients they need to test disease modifying treatment[2].

See all Members